Edition:
United Kingdom

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

22.68USD
14 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$22.68
Open
$23.22
Day's High
$23.49
Day's Low
$21.75
Volume
14,581
Avg. Vol
28,328
52-wk High
$25.57
52-wk Low
$7.74

Latest Key Developments (Source: Significant Developments)

Kalvista Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Kalvista Pharmaceuticals Reports Fiscal Second Quarter Results
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS.KALVISTA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.22.KALVISTA PHARMACEUTICALS - KVD900 ENLARGED PHASE 2 TRIAL ON TRACK FOR POTENTIAL ON-DEMAND TREATMENT OF ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA.KALVISTA PHARMACEUTICALS INC - INTRAVITREAL DIABETIC MACULAR EDEMA CANDIDATE KVD001 PHASE 2 TRIAL ENROLLMENT ON TRACK.KALVISTA PHARMACEUTICALS INC - OPERATIONS FUNDED INTO 2021.KALVISTA PHARMACEUTICALS INC - QTRLY REVENUE $5.6 MILLION VERSUS $1.1 MILLION.  Full Article

Kalvista Pharmaceuticals Provides Clinical Update On Kvd900
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS PROVIDES CLINICAL UPDATE ON KVD900.KALVISTA PHARMACEUTICALS - ENLARGED PHASE 2 STUDY TO BEGIN IN 2018 FOR POTENTIAL ACUTE TREATMENT OF HEREDITARY ANGIOEDEMA; DATA EXPECTED IN LATE 2019.KALVISTA PHARMACEUTICALS INC - FOOD EFFECT STUDY INDICATES NO DOSING LIMITATIONS FROM FOOD AND CONFIRMS RAPID UPTAKE AND HIGH EXPOSURE.  Full Article

Kalvista Pharmaceuticals Announces Pricing Of Stock Offering
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.KALVISTA PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 4 MILLION SHARES OF COMMON STOCK AT A PRICE TO PUBLIC OF $17.00 PER SHARE.  Full Article

Kalvista Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.KALVISTA PHARMACEUTICALS - TO USE PROCEEDS OF OFFERING TO FUND LATE-STAGE DEVELOPMENT OF KVD900, AMONG OTHERS.  Full Article

Kalvista Pharmaceuticals Commences Two Clinical Trials
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS COMMENCES TWO CLINICAL TRIALS.KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001.KALVISTA PHARMACEUTICALS INC - EXPECTS TO PROVIDE AN UPDATE ON STATUS AND PROGRESS OF HAE PORTFOLIO, INCLUDING KVD900, IN MID-2018.  Full Article

Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $1.1 MILLION VERSUS $200,000.  Full Article

Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Kalvista Pharmaceuticals Inc :Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​.  Full Article

Kalvista Pharmaceuticals announces collaboration with Merck
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Kalvista Pharmaceuticals Inc :Kalvista Pharmaceuticals announces collaboration with Merck.Kalvista Pharmaceuticals - ‍investigational intravitreal DME candidate KVD001 phase 2 clinical trial still planned to initiate in 2017​.Kalvista Pharmaceuticals Inc - ‍Merck acquires 9.9% stake in Kalvista in private placement​.Kalvista Pharmaceuticals Inc - deal includes ‍$37 million upfront fee plus potential milestone payments and sales royalties​.Kalvista Pharmaceuticals Inc - ‍Kalvista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME​.Kalvista - ‍under deal terms, co granted to Merck rights including an option to acquire KVD001 through a period following completion of phase 2 trial.Kalvista - Co will fund, retain control over planned phase 2 clinical trial of KVD001, development of investigational oral DME compounds through phase 2​.Kalvista - eligible to get payments associated with exercise of options by Merck, achievement of milestones for each program potentially total $715 million​.  Full Article